Century Therapeutics, Inc.
NEWS
The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.
BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week.
Century Therapeutics received a $160 million infusion of cash to advance the company’s pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Century’s iPSCs, which are stem cells that can be generated from adult stem cells, have unlimited self-renewing capacity, the company said, which enables multiple rounds of cellular engineering.
JOBS
IN THE PRESS